Skip to Content
You are currently on the new version of our website. Access the old version .
  • 2.9
    Impact Factor
  • 4.6
    CiteScore
  • 18 days
    Submission to First Decision
  • 3 days
    Acceptance to Publication

Medicina

Medicina is an international, peer-reviewed, open access journal covering all problems related to medicine, published monthly online. It is the official journal of the Lithuanian University of Health Sciences (LUHS). The Lithuanian Medical Association (LMA), Vilnius University, Rīga Stradiņš University, University of Latvia, and University of Tartu are affiliated with Medicina, serving as their official journal. Members of these organizations receive discounts on the article processing charges.
  • Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
  • High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, and other databases.
  • Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)
  • Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.4 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).
  • Recognition of Reviewers: Reviewers whose reports are timely and of high quality receive an APC discount voucher for a future publication in an MDPI journal. Become a reviewer.

Get Alerted

Add your email address to receive forthcoming issues of this journal.

All Articles (14,647)

  • Article
  • Open Access

Objectives: Acute coronary syndrome (ACS), pulmonary embolism (PE), and aortic dissection (AD) present with overlapping symptoms but require markedly different treatments. We investigated whether cardiac quantitative parameters obtained by automated segmentation of non-contrast and contrast-enhanced chest CT can support machine learning-based multiclass differentiation of these conditions. Materials and Methods: This single-center retrospective study included 628 patients who underwent triple rule-out CT angiography (147 negative controls, 193 ACS, 147 PE, and 141 AD). Twenty-six features were extracted separately from automated cardiac segmentation of non-contrast and contrast-enhanced images. Five classifiers—multivariable logistic regression, random forest, XGBoost, LightGBM, and support vector machine—were developed with a 7:3 stratified train–test split and five-fold cross-validation. Performance was evaluated by accuracy, macro-averaged F1 score, and macro-averaged area under the receiver operating characteristic curve (AUC), and feature importance was assessed with SHapley Additive exPlanations (SHAP). Results: Multivariable logistic regression showed the most balanced performance for both modalities. The non-contrast model achieved an accuracy of 0.635, a macro-averaged F1 score of 0.637, and a macro-averaged AUC of 0.840, with class-specific AUCs of 0.814 for ACS, 0.878 for PE, and 0.887 for AD. The contrast-enhanced model achieved 0.683, 0.673, and 0.861, with AUCs of 0.881, 0.876, and 0.919. Recall for ACS increased from 58.6% to 70.7% and for AD from 74.4% to 83.7%, while AD cases misclassified as negative decreased from 11.6% to 2.3%. Left ventricular mass index and right-heart parameters ranked among the most contributory features in both models. Conclusion: Machine learning models built on automatically segmented cardiac parameters showed moderate discriminatory potential for differentiating ACS, PE, and AD. The contrast-enhanced model outperformed the non-contrast model, whereas non-contrast CT still carried complementary structural information that may support risk stratification before contrast administration.

Medicina

11 November 2026

Non-contrast and contrast-enhanced chest CT images with automated cardiac segmentation overlays in a patient with aortic dissection (AD). (A) Non-contrast CT image; (B) automated segmentation overlay on the non-contrast image; (C) contrast-enhanced CT image; (D) automated segmentation overlay on the contrast-enhanced image. In (B,D), Green indicates the left ventricular myocardium; brown, the left ventricular cavity; red, the right ventricular cavity; yellow, the left atrial cavity; and blue, the right atrial cavity.
  • Review
  • Open Access

Background and Objectives: Adropin is a peptide involved in metabolic regulation and vascular function, but its role in exercise adaptation remains uncertain. This narrative review synthesizes evidence on adropin responses to exercise, factors that may influence these responses, and their relationships with metabolic and vascular adaptation. Materials and Methods: A structured literature search was conducted in PubMed, Embase, and Cochrane Library from database inception to August 2026, supplemented by reference-list screening. Two reviewers independently assessed full texts and selected relevant articles. Disagreements were resolved through discussion with a third reviewer. Human exercise studies, observational studies of physiological factors, and experimental studies of metabolic and vascular mechanisms were synthesized narratively. Results: Human studies generally reported increased circulating adropin after aerobics, interval, resistance, and combined training. These increases were associated with improvements in cardiorespiratory fitness, glucose regulation, endothelial function, or arterial stiffness. However, acute responses were not consistently observed, and differences in populations, exercise protocols, and sampling conditions limited comparisons. Age, adiposity, metabolic status, hormonal factors, and nutrition were associated with baseline adropin concentrations, but direct evidence that these factors modify training responses remained limited. Experimental studies support effects on skeletal muscle substrate utilization, insulin signaling, and endothelial nitric oxide production. These findings provide biological plausibility but do not establish that exercise-induced changes in circulating adropin mediate human adaptations. One small, randomized trial reported an exploratory indirect effect on arterial stiffness through adropin. Small samples, uncontrolled comparisons, measurement differences, and reliance on observational and preclinical evidence limit interpretation. Conclusions: Adropin is an exercise-responsive biomarker candidate and a potential biological mediator whose causal role remains unresolved. Current evidence does not establish an optimal exercise modality or dose for increasing adropin. Standardized measurements and studies that establish temporal relationships and test mediation are needed to determine whether adropin provides information beyond established metabolic and vascular outcomes.

Medicina

11 November 2026

Exercise-related variability in circulating adropin and its associations with metabolic and vascular outcomes in humans.
Conceptual framework illustrating the translation of technological and surgical innovation into clinically meaningful, patient-centered outcomes through technical assessment, clinical validation, and methodological rigor in orthopedics and trauma surgery.
  • Article
  • Open Access

Background and Objectives: Sodium-glucose cotransporter type 2 (SGLT-2) inhibitors provide substantial cardiovascular and renal benefits, but concerns regarding urinary tract infections (UTIs) may limit their use. This study aimed to evaluate the incidence and management of lower UTIs among patients receiving SGLT-2 inhibitors compared to other patients and to identify associated risk factors in primary care. Materials and Methods: This retrospective observational study included 5764 adults from four family medicine practices from November 2024 to October 2025. Patients were categorized according to lower UTI occurrence, complexity, and SGLT-2 inhibitor use. Demographic characteristics, comorbidities, laboratory parameters, treatment duration, urine cultures, and antibiotic therapy were analyzed. Results: Lower UTIs occurred in 567 patients (9.8%), of whom 30 (16.3%) were taking SGLT-2 inhibitors, and were more frequent among women and patients with diabetes, chronic kidney disease (CKD), benign prostatic hyperplasia (BPH), urolithiasis, and permanent urinary catheters. Except for urolithiasis, all these factors were also independent predictors of lower UTI development in the logistic regression model. In contrast, patients taking an SGLT-2 inhibitor had 43.8% lower odds of developing a UTI, though this may reflect temporal relationship bias. SGLT-2 inhibitors were prescribed to 24.2% of patients with type 2 diabetes, while their use for CKD and heart failure was limited. Family physicians managed 90% of uncomplicated and 64% of complicated lower UTIs. Urine cultures were performed in less than one-third of these patients. Nitrofurantoin was prescribed as the first-choice antibiotic regardless of UTI complexity, predominantly by family physicians. Hospital specialists more often choose fluoroquinolones, followed by cephalosporins. Conclusions: Despite increased lower UTI incidence among patients receiving SGLT-2 inhibitors, their use was not associated with lower UTI development. Urine cultures were insufficiently utilized in patients with UTIs, and they were predominantly not treated according to the latest guidelines. SGLT-2 inhibitors were also underused, particularly for CKD and heart failure, suggesting a potential gap between recommendations and clinical practice.

Medicina

11 November 2026

Number of participants in each group, by whether they had a lower urinary tract infection (UTI) and were treated with a sodium-glucose cotransporter 2 (SGLT-2) inhibitor.

Featured Articles of Last Quarter

Highly Accessed Articles

News & Conferences

Latest Issues

Open for Submission

Journal Sections

XFacebookLinkedIn
Medicina - ISSN 1648-9144